Proteomics International said it has signed a material transfer agreement with the University of Oxford to acquire roughly 600 patient plasma samples for an endometriosis study.
The Company said it will use the samples to further validate its PromarkerEndo proteomic test for endometriosis. The test is intended as an early screening test to help rule in or rule out the disease and determine if more invasive diagnostic testing is needed.
This validation work follows a previous study in which the test was used in more than 900 patients and a separate clinical validation study in an independent Australian cohort.
